Work

Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ)

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2022-ct170

Authors: Michael Cecchini, Joseph Chao, Yu Shyr, James Cleary, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristin Spencer, Edward Kim, Chih-Yuan Hsu, Stacey Stein, Jaykumar Thumar, Jeremy Kortmansky, John Kunstman, Patricia LoRusso, Percy Ivy, Jill Lacy

Institutions: Yale University, City Of Hope National Medical Center, Vanderbilt University, Dana-Farber Cancer Institute, University of Wisconsin System, University of Wisconsin–Madison, University of California, Irvine, The Barbara Ann Karmanos Cancer Institute, The University of Texas MD Anderson Cancer Center, Rutgers Cancer Institute, University of California, Davis, National Cancer Institute

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282967441

Cites:

Cited by: 1

Related to: 10